713 related articles for article (PubMed ID: 26104022)
1. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
[TBL] [Abstract][Full Text] [Related]
2. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
3. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Helicobacter; 2016 Oct; 21(5):382-8. PubMed ID: 26809022
[TBL] [Abstract][Full Text] [Related]
4. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
van der Wouden EJ; Thijs JC; van Zwet AA; Kooy A; Kleibeuker JH
Am J Gastroenterol; 1998 Aug; 93(8):1228-31. PubMed ID: 9707042
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
8. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.
Tsay FW; Wu DC; Kao SS; Tsai TJ; Lai KH; Cheng JS; Chan HH; Wang HM; Tsai WL; Tseng HH; Peng NJ; Hsu PI
Helicobacter; 2015 Feb; 20(1):71-7. PubMed ID: 25495272
[TBL] [Abstract][Full Text] [Related]
9. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
[TBL] [Abstract][Full Text] [Related]
10. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
11. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
[TBL] [Abstract][Full Text] [Related]
13. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
[TBL] [Abstract][Full Text] [Related]
14. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
de Boer WA; Haeck PW; Otten MH; Mulder CJ
Am J Gastroenterol; 1998 Jul; 93(7):1101-7. PubMed ID: 9672338
[TBL] [Abstract][Full Text] [Related]
17. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Song Z; Suo B; Tian X; Ren X; Xue Y; Niu Z; Zhou L
Dig Liver Dis; 2023 May; 55(5):601-607. PubMed ID: 36646526
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
[TBL] [Abstract][Full Text] [Related]
19. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
